FOLD vs. RGEN, MDGL, IONS, ALKS, BCRX, LGND, MNKD, CLDX, DVAX, and INVA
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
Amicus Therapeutics vs.
Repligen (NASDAQ:RGEN) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
Repligen currently has a consensus target price of $173.25, suggesting a potential upside of 35.79%. Amicus Therapeutics has a consensus target price of $16.22, suggesting a potential upside of 146.16%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Repligen.
In the previous week, Repligen had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 9 mentions for Repligen and 8 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.60 beat Repligen's score of 1.28 indicating that Amicus Therapeutics is being referred to more favorably in the news media.
97.6% of Repligen shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Amicus Therapeutics received 115 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 72.81% of users gave Amicus Therapeutics an outperform vote while only 67.09% of users gave Repligen an outperform vote.
Repligen has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Repligen has higher revenue and earnings than Amicus Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Repligen has a net margin of -4.64% compared to Amicus Therapeutics' net margin of -10.62%. Amicus Therapeutics' return on equity of 12.44% beat Repligen's return on equity.
Summary
Repligen and Amicus Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FOLD) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy FOLD Stock Free FOLD Stock Alerts